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Abstract
The establishment of a DNA synthesis and construction foundry at Imperial College in London heralds a new
chapter in the development of synthetic biology to meet new global challenges. The Foundry employs the
latest technology to make the process of engineering biology easier, faster and scalable. The integration
of advanced software, automation and analytics allows the rapid design, build and testing of engineered
organisms.
Introduction
The publication of the Roadmap for Synthetic Biology
in 2012 and its recommendations resulted in significant
U.K. Government investment in synthetic biology. Over
£100 million was invested through the Research Councils
U.K. and Innovate U.K. to establish six new Synthetic
Biology Research Centres (SBRCs: Universities of Bristol,
Edinburgh,Manchester,Nottingham,Cambridge/John Innes
Centre and Warwick), four Doctoral Training Centres
(DTCs: Universities of Oxford, Bristol, Warwick and
University College, London) and an Innovation and
Knowledge Centre (IKC: SynbiCITE at Imperial College,
London) to drive the commercial translation of synthetic
biology research. The U.K. Government’s commitment to
the commercialization of synthetic biology was further
reinforced with an additional £10 million investment in
the Rainbow Seed Fund for synthetic biology spinouts
and start-ups. One of the more innovative initiatives to
come out of this investment was the creation of a U.K.
DNA synthesis capability to support synthetic biology
academic research and commercial translation. In total, five
DNA Synthesis Foundries were established (Edinburgh
Genome Foundry, Liverpool Gene Mill, MRC Laboratory
of Molecular Biology, DNA Synthesis and Construction
Foundry at Imperial College and The Genome Analysis
Centre at Norwich Research Park).
The DNA Synthesis and Construction Foundry at
Imperial College (the Foundry) is located at SynbiCITE,
which operates from the Imperial Incubator. SynbiCITE as
the national centre for the translation and commercialization
of synthetic biology provides a number of innovation
programmes to its academic and industrial partners. These
innovation programmes are specifically designed to provide
early-stage business support and include: education and
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training, funding for proof of concept and development of
prototypes and business support. An important element in
the innovation programmes SynbiCITE provides is access to
its laboratory facilities, including – the Foundry. This access
provides scientists and researchers with a maker space for the
rapid translation of ideas and designs: producing a prototype
or generating critical data – all geared towards advancing
technology, removing the technical uncertainty and risk
in the process. This facility is available to SynbiCITE’s
extensive network of partners including 17 U.K. universities
and over 50 industrial and commercial partners, made-up of
multinational companies, SMEs and start-ups.
Focus
SynbiCITE with its specific focus on commercial translation
employs the Foundry to provide a suite of state-of-the-
art robotic and analytical equipment supplying end-to-end
design, construction and characterization capability to its
partners. Work is focused on industry-led projects with
commercial or practical applications, which can benefit from
the Foundry’s automated higher throughput and capacity.
Goals
1. Build a state-of-the-art DNA Synthesis and Construction
Foundry. Operated as a series of modular automated
workstations the Foundry provides an integrated, flexible
assembly platform capable of delivering biological design
automation at scale.
2. Develop the U.K. capability and infrastructure for syn-
thetic biology. The creation and operation of standardized
workflows and software forDNAsynthesis, assembly and
verification of large DNA assemblies (>50 kb), including
chromosome synthesis at scale.
3. Support the U.K. industrial base in synthetic biology.
The Foundry as part of SynbiCITE, the national IKC
for Synthetic Biology, will provide access, collaboration
Biochem. Soc. Trans. (2016) 44, 687–688; doi:10.1042/BST20160007
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence
4.0 (CC BY).
688 Biochemical Society Transactions (2016), Volume 44, part 3
and training opportunities to U.K. companies interested
in synthetic biology.
4. Provide support and training programmes. The Foundry,
in collaboration with its partners, act as a focal point for
the training of researchers (both academic and industrial)
in the synthesis and construction of DNA, at scale, in
relation to synthetic biology applications.
Facilities and resources
The Foundry’s facilities and resources are available to all
SynbiCITE academic and industrial partners – providing
access to both equipment and expertise. A list of all the
equipment is available atwww.synbicite.com. To keep abreast
of the fast pace of technology development in synthetic
biology, the facilities and resources available at the Foundry
will evolve to meet demand. The Foundry has continued
access to the latest cutting edge technology, required to
stimulate innovation in synthetic biology, is made possible
through a number of special collaborations with industrial
partners supplying resources and expertise.
People with the correct skills are key to the successful
adoption of synthetic biology by industry. We also recognize
that this new industry depends on people with the right skill-
set to translate their ideas. SynbiCITE is therefore committed
to sharing new approaches and discoveries in synthetic
biology with its partners by providing scientific workshops
and technical training on all equipment and platforms.
A major aim of the Foundry (and synthetic biology) is
to make the design and engineering of biological systems
systematic and standardized around a ‘design-build-test-
report-learn’ cycle. The Foundry has been specifically built
to support and exploit this framework.
The facilities and accompanying capabilities include:
 A range of commercial and proprietary BioCAD/CAM
tools for the rapid and scalable design of transgenes and
experiments.
 Conventional and acoustic liquid handling robotic plat-
forms to build and assemble multiple DNA components
in parallel. Supported by software for programming and
scheduling automation.
 A suite of high-throughput analytical/test equipment
for metadata acquisition allowing characterization and
quantification across the range of biological products.
 A web-based Laboratory Information Management Sys-
tem (LIMS) to report on the tracking of the workflow for
any assembly or experiment. The LIMS tracks the users’
specifications containing the product design, the entire
construction sequence including replicating reagents, PCR
and assembly; and the sample reagent lineage, location and
availability.
 The engineering-design cycle is completed with data
analytics, providing the learn capability with statistical
interpretation and modelling which can feedback into the
design loop.
The Foundry and SynbiCITE, both represent a unique
public–private collaborative effort to accelerate and promote
business exploitation of emerging research and technology
around synthetic biology. The Foundry intends to deliver
a key resource to the U.K. synthetic biology industrial and
academic community seeking to commercialize their ideas
and research.
Funding
This work was supported by the DNA Synthesis Capital Awards [grant
numbers BB/L027852/1 (to P.F.) and BB/M025632/1 (to R.I.K.)].
Received 15 January 2016
doi:10.1042/BST20160007
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence
4.0 (CC BY).
